ストックスクリーナーアプリを入手
0.3838
5.47%
0.0199
プレマーケット:
.39
0.0062
+1.62%
前日終値:
$0.3639
開ける：
$0.3625
24時間の取引高:
2.06M
Relative Volume:
0.55
時価総額：
$40.74M
収益：
$36.86M
当期純損益:
$-171.67M
株価収益率:
-0.2559
EPS:
-1.5
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
+17.41%
1か月 パフォーマンス:
+1.13%
6か月 パフォーマンス:
-81.19%
1年 パフォーマンス:
-86.95%
1日の値動き範囲:
$0.355
$0.3929
1週間の範囲:
$0.3301
$0.4298
52週間の値動き範囲:
$0.2589
$3.63
Mersana Therapeutics Inc Stock (MRSN) Company Profile
MRSN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.3838 | 40.74M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | 開始されました | William Blair | Outperform |
| 2024-11-15 | 再開されました | Citigroup | Buy |
| 2024-03-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-02-29 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-02-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-02-29 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-12-04 | アップグレード | Citigroup | Neutral → Buy |
| 2023-07-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-07-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-07-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-07-27 | ダウングレード | Truist | Buy → Hold |
| 2023-07-27 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-06-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 開始されました | Guggenheim | Buy |
| 2023-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 開始されました | Citigroup | Buy |
| 2022-11-21 | 開始されました | Truist | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-04-29 | 開始されました | BTIG Research | Buy |
| 2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-11-14 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Mersana Therapeutics Inc (MRSN) 最新ニュース
Investors’ Faith in Mersana Therapeutics Inc (MRSN) could reap rewards if they hold on for the long haul - uspostnews.com
Investor’s Delight: Mersana Therapeutics Inc (MRSN) Closes Strong at 0.36, Up 0.44 - DWinneX
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Stock Holdings Lifted by Geode Capital Management LLC - Defense World
MRSN Shares Experience Decline in Value - knoxdaily.com
Mersana therapeutics VP Mandelia sells $1,128 in stock - MSN
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting | MRSN Stock News - GuruFocus
Mersana Therapeutics Announces Presentations on Emiltatug Ledadotin at ASCO 2025 Annual Meeting - Nasdaq
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting - GlobeNewswire
Breakthrough Cancer Drug Emi-Le Earns Dual FDA Fast Track Status: Key Data Coming at ASCO 2025 - Stock Titan
Daily Market Movement: Mersana Therapeutics Inc (MRSN) Sees a 15.02 Increase, Closing at 0.38 - DWinneX
Mersana Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
It makes sense and dollars to buy Mersana Therapeutics Inc (MRSN) stock - Sete News
Mersana Therapeutics Inc [MRSN] Insider Activity: An Update for Investors - knoxdaily.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Wellington Management Group LLP - Defense World
Sei Investments Co. Purchases Shares of 69,527 Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MRSN stock touches 52-week low at $0.3 amid sharp annual decline - Investing.com
Mersana Strengthens Team with Strategic 26,790-Share RSU Grant to New Hire - Stock Titan
MRSN stock touches 52-week low at $0.3 amid sharp annual decline By Investing.com - Investing.com South Africa
When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress - The Manila Times
Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire
FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India
MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st
Drug developers show mixed performance in early 2025 - BioWorld MedTech
MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia
Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada
MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat
Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St
Mersana Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Q1 EPS Estimate for Mersana Therapeutics Reduced by Analyst - Defense World
Brokers Issue Forecasts for MRSN Q1 Earnings - Defense World
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript - Insider Monkey
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Mersana Therapeutics (NASDAQ:MRSN) Receives “Outperform” Rating from Wedbush - Defense World
Mersana Therapeutics Inc (MRSN) 財務データ
収益
当期純利益
現金流量
EPS
0.19%
大文字化:
|
ボリューム (24 時間):